BASKING RIDGE, N.J., May 30 /PRNewswire-FirstCall/ -- Millennium Biotechnologies, Inc. a wholly owned subsidiary of Millennium Biotechnologies Group, Inc. announced today that it has received a $238,000 purchase order from New Marketlink Pharmaceutical Corp., a Philippine pharmaceutical company for the distribution and marketing of its Resurgex(R) product line for the oncology market.
New Marketlink Pharmaceutical Corp. will distribute and market the line of Resurgex(R) products for cancer patients in the Philippines. Following the launch in the Philippines distribution is expected to expand to Korea, Malaysia, Singapore, Thailand, Vietnam, Taiwan and Indonesia. As for all new products which are imported into the Philippines the purchase order is subject to the issuance of a certificate of product registration. The certificate of product registration is subject to approval by the Philippine Regulatory Agency (BFAD).
"Recently, several distribution channels have opened up to Resurgex (R) products due to the overwhelming recognition of the superiority of the Resurgex(R) ingredients compared with other products in the market place. We expect this is the first of those to trigger revenue growth along with the recently announced P4 Healthcare product launch scheduled for June 2007," said Jerry Swon, Sr., President of Millennium Biotechnologies Group, Inc. For more information on P4 Healthcare, please visit their website at http://www.caring4cancer.com
Resurgex Select(R) was developed to provide a superior source of high- quality calories as opposed to the corn oil and corn syrup-laden products that are found in the marketplace. As with the previous patent issued for Resurgex(R), this additional patent serves to protect the intellectual property of Millennium's new addition to the Resurgex(R) family of products.
About Millennium Biotechnologies, Inc.: Millennium Biotechnologies, Inc. is a research-based nutraceutical company and a pioneer in the emerging field of specialized nutritional supplements. The company's flagship products, RESURGEX(R), RESURGEX Plus(R), and RESURGEX Select(R), are designed to assist in reducing fatigue and oxidative stress, maintaining lean muscle and immune support in immunocompromised conditions.
Millennium Biotechnologies, Inc. is a wholly owned subsidiary of Millennium Biotechnologies Group, Inc., a publicly-traded company . For more information about Millennium Biotechnologies, please contact Jerry Swon, Chief Executive Officer, at jswon@milbiotech.com or call (908) 604-2500. For more information about the Resurgex line of products visit http://www.resurgex.com.
This release includes certain forward-looking information that is based upon management's beliefs as well as on assumptions made by and data currently available to management. This information which has been, or in the future may be, included in reliance on the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, is subject to a number of risks and uncertainties, including but not limited to uncertainty as to market acceptance of Resurgex and Resurgex Plus and the factors identified in the Company's 10-KSB and other documents filed with the Securities and Exchange Commission. Actual results may differ materially form those anticipated in such forward-looking statements even if experience or future changes make it clear the any projected results expressed or implied therein may not be realized. The Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.
Millennium Biotechnologies, Inc.CONTACT: Jerry Swon, Chief Executive Officer of MillenniumBiotechnologies, Inc., +1-908-604-2500, jswon@milbiotech.com
